RÉSUMÉ
This study was aimed to investigate the clinical effect of tetramethylpyrazine in combination with ipratropium bromide in the treatment of bronchial asthma and its effects on inflammatory factors and leptin. According to inclusion criteria, a total of 124 bronchial asthma cases were included and randomly divided into two groups, which were the control group (n = 62) and the observation group (n = 62) with the random number table. Besides conventional treatments, the control group was given ipratropium bromide; while the observation group was given tetramethylpyrazine in combination with ipratropium bromide. Then, comparisons were made between two groups on the therapeutic efficacy rate, pulmonary function, inflammatory factor, leptin, and incidence of adverse reactions. The results showed that the total therapeutic efficacy rate was 96.8% in the observation group, which was obviously higher than that of 87.1% in the control group (P 0.05). It was concluded that tetramethylpyrazine in combination with ipratropium bromide was effective for bronchial asthma treatment, which can significantly increase curative efficacy, improve pulmonary function, alleviate inflammatory reaction and reduce leptin level with minor adverse reactions. It required further studies in the clinical practice.